Table 1 Overview of the study design to evaluate the preventive efficacy of Bravecto® Plus spot-on solution at the minimum recommended dose (2.0 mg moxidectin/kg BW + 40 mg fluralaner/kg) compared to placebo treatment (0.9% saline solution)
| Group | No. of cats | Treatment (study day) | Infection with 300 Aelurostrongylus abstrusus L3 (study day) | Necropsy (study day) | |
|---|---|---|---|---|---|
| 1 | 8 | 0 | Bravecto® Plus spot-on solution | 84 | 131–134 |
| 28 | Placebo | ||||
| 56 | Placebo | ||||
| 2 | 8 | 0 | Placebo | ||
| 28 | Bravecto® Plus spot-on solution | ||||
| 56 | Placebo | ||||
| 3 | 7 | 0 | Placebo | ||
| 28 | Placebo | ||||
| 56 | Bravecto® Plus spot-on solution | ||||
| 4 | 8 | 0 | Placebo | ||
| 28 | Placebo | ||||
| 56 | Placebo | ||||